Clinical Trials Directory

Trials / Completed

CompletedNCT02270931

A Prospective Longitudinal Breast Cancer Study

A Prospective Longitudinal Study of CA 15-3 as an Aid in Monitoring Recurrence or Progressive Disease in Patients With Breast Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
130 (estimated)
Sponsor
Fujirebio Diagnostics, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of breast cancer.

Detailed description

The study objectives are described below: 1. Obtain serum and plasma specimens longitudinally collected from a minimum of 130 subjects diagnosed with breast cancer and are about to or are currently undergoing treatment and follow-up. Specimens will be used to evaluate CA 15-3 assays, currently under development, as an aid for monitoring recurrence or progressive disease. 2. To store any remaining specimens for use in future cancer research and to evaluate as yet undetermined biomarkers for the development of IVDs, including additional CA 15-3 assays, for monitoring the course of disease and therapy in subjects diagnosed with breast cancer.

Conditions

Interventions

TypeNameDescription
DEVICECA 15-3 AssayPhysicians use the CA 15-3 test result to manage their patients

Timeline

Start date
2014-05-01
Primary completion
2021-06-30
Completion
2021-06-30
First posted
2014-10-22
Last updated
2021-08-17

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02270931. Inclusion in this directory is not an endorsement.